Navigation Links
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Date:11/10/2008

Complete Remission / Unconfirmed Complete Remission Rate 3.5 Fold Higher

Compared to Standard Chemotherapy

SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778) for patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) based on a preliminary intent to treat efficacy analysis. Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increased the overall response rate (CR/uCR+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003). CR/uCR and ORR were determined by an independent assessment panel that was blinded to the treatment assignments. The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent Data Safety Monitoring Committee and no serious concerns were raised. Seventy-four percent of patients discontinued therapy for disease progression or death, the majority of which were in the standard chemotherapy control arm.

CTI plans to submit complete study data for presentation at a major scientific conference. CTI also intends to request a pre-NDA meeting with the FDA and expects to begin submission of a rolling New Drug Application (NDA) to the FDA in early 2009.

"This positive phase II
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
2. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
5. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
6. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
7. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
8. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
9. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
10. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
11. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... 14 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... Drug Application (NDA) for Staccato® loxapine (AZ-004) to the ... an inhalation product candidate being developed for the rapid ... disorder. The IND for Staccato loxapine ... "AZ-004 has delivered a predictable and consistent safety and ...
(Date:12/14/2009)... DUBLIN, Ohio, Dec. 14 Cardinal Health today ... at the following events: ,, Goldman Sachs ... EST at the Goldman Sachs Conference Center in New ... on Jan. 12 at Noon EST at the ... At these events, company executives will discuss Cardinal Health,s ...
(Date:12/14/2009)... CHICAGO, Dec. 14 Sword Diagnostics, Inc. ... Patent Office (USPTO) has issued patent number ... Biological Organisms using Raman Scattering" to the company. ... on improved sensitivity. ,, "The issuance of ... move forward with our continued development and commercialization," ...
Breaking Medicine Technology:Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 4Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 5Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 6Cardinal Health Executives to Speak at Two Investor Events in January 2IDEAL LIFEs Remote Monitoring System Benefits Rural North Carolina Communities 53465 1IDEAL LIFEs Remote Monitoring System Benefits Rural North Carolina Communities 53465 2IDEAL LIFEs Remote Monitoring System Benefits Rural North Carolina Communities 53465 3New Surgical Device Revolutionizes Face Lifts Abdominoplasty and Breast Reduction Surgery Promising Patients Quicker Recovery Time Less Pain and Few 53461 1New Surgical Device Revolutionizes Face Lifts Abdominoplasty and Breast Reduction Surgery Promising Patients Quicker Recovery Time Less Pain and Few 53461 2New Surgical Device Revolutionizes Face Lifts Abdominoplasty and Breast Reduction Surgery Promising Patients Quicker Recovery Time Less Pain and Few 53461 3STAAR Surgical Generates Cash From Operations During Second Quarter 53456 1STAAR Surgical Generates Cash From Operations During Second Quarter 53456 2STAAR Surgical Generates Cash From Operations During Second Quarter 53456 3STAAR Surgical Generates Cash From Operations During Second Quarter 53456 4STAAR Surgical Generates Cash From Operations During Second Quarter 53456 5STAAR Surgical Generates Cash From Operations During Second Quarter 53456 6STAAR Surgical Generates Cash From Operations During Second Quarter 53456 7STAAR Surgical Generates Cash From Operations During Second Quarter 53456 8STAAR Surgical Generates Cash From Operations During Second Quarter 53456 9STAAR Surgical Generates Cash From Operations During Second Quarter 53456 10STAAR Surgical Generates Cash From Operations During Second Quarter 53456 11STAAR Surgical Generates Cash From Operations During Second Quarter 53456 12STAAR Surgical Generates Cash From Operations During Second Quarter 53456 13STAAR Surgical Generates Cash From Operations During Second Quarter 53456 14STAAR Surgical Generates Cash From Operations During Second Quarter 53456 15STAAR Surgical Generates Cash From Operations During Second Quarter 53456 16STAAR Surgical Generates Cash From Operations During Second Quarter 53456 17STAAR Surgical Generates Cash From Operations During Second Quarter 53456 18STAAR Surgical Generates Cash From Operations During Second Quarter 53456 19STAAR Surgical Generates Cash From Operations During Second Quarter 53456 20STAAR Surgical Generates Cash From Operations During Second Quarter 53456 21STAAR Surgical Generates Cash From Operations During Second Quarter 53456 22
(Date:12/14/2009)... is small and shouldn,t worry most users, researcher says ... who take antidepressants may have a small but statistically ... women not on the medications, a new study finds. ... significance," stressed Dr. Jordan W. Smoller, an associate professor ... of a report in the Dec. 14 issue of ...
(Date:12/14/2009)... to better treatments for asthma, COPD, researchers say , , ... five genetic variants that influence lung function, a finding ... diseases. , The international team of researchers compared lung ... million sites across the human genome in more than ... to the five common genetic variants associated with alterations ...
(Date:12/14/2009)... in-home caregivers who have been certified by the Alzheimer’s Association ... and hospice services to San Francisco Bay Area families. ... ... 14, 2009 -- Professional HealthCare at Home, the San Francisco ... nursing, rehab, personal caregiver and hospice services, has expanded its ...
(Date:12/14/2009)... Dec. 14 Following is a statement ... Kids: ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) ,, The ... the National Institute of Drug Abuse shows that ... reducing youth smoking, but declines have slowed significantly ... decade. In especially troubling news, the survey ...
(Date:12/14/2009)... of urban teenage girls may acquire at least one ... years of becoming sexually active, according to an Indiana ... , The study appears in the December 2009 issue ... , The researchers followed 381 girls enrolled at ages ... with the organisms that cause chlamydia, gonorrhea and trichomoniasis ...
Breaking Medicine News(10 mins):Health News:Antidepressants May Raise Women's Stroke Risk 2Health News:Antidepressants May Raise Women's Stroke Risk 3Health News:Caregivers with Professional HealthCare at Home Now Certified by the Alzheimer's Association 2Health News:New Survey Shows Slow Decline in Youth Smoking, Troubling Increase in Smokeless Tobacco Use - Congress, States Must Step Up Tobacco Prevention Efforts 2Health News:New Survey Shows Slow Decline in Youth Smoking, Troubling Increase in Smokeless Tobacco Use - Congress, States Must Step Up Tobacco Prevention Efforts 3Health News:New Survey Shows Slow Decline in Youth Smoking, Troubling Increase in Smokeless Tobacco Use - Congress, States Must Step Up Tobacco Prevention Efforts 4Health News:New Survey Shows Slow Decline in Youth Smoking, Troubling Increase in Smokeless Tobacco Use - Congress, States Must Step Up Tobacco Prevention Efforts 5Health News:IU study: Half of urban teen girls acquire STIs within 2 years of first sexual activity 2
... published a study-- HIV can mutate key proteins in order ... occur they persist. ,When HIV attacks, the cell alerts ... surface. This is a suicide signal to kill the infected ... ability to recognise the displayed HIV fragment. , ,The ...
... more heart-friendly products has been developed by European scientists. ... UK and colleagues, describe how they boosted the production ... tomatoes. Rutin is a flavonol, part of a larger ... be a powerful antioxidant.// ,The researchers noticed ...
... study provides further evidence that nutrient antioxidants play a ... from Tufts University studied more than 575 women ages ... women did not have diabetes nor did they have ... answered questionnaires about their food intake.// They were also ...
... stroke in the US occur among postmenopausal women. Many of ... risk be detected?// ,One way may be through ... stroke risk is atheroma - fatty deposits in the carotid ... a dental x-ray. Researchers in California have assessed dental x-rays ...
... relief of the pain and inflammation of osteoarthritis and ... and stiffness of arthritis, celebrex can help you through ... stairs, and through the night while sitting or lying ... drugs, which are known technically as COX-2 inhibitors, have ...
... at Vanderbilt University and the National Institutes of Health say ... women should be raised from 75 to 90 milligrams a ... more than satisfy the recommended allowance, said Dr. Mark Levine, ... women.'We've been recommending, as have other groups, that both men ...
Other Medicine News:Health News:Eat Vitamin C and stay young 2
Foley Catheters (Latex) 2-Way...
Silicone Elastomer-Coated Latex Foley Catheters 2-Way (Pediatric)...
Midstream Catch Kits...
Midstream Catch Kits...
Medicine Products: